Anti-BCMA CAR T-Cell Therapy in Relapsed or Refractory Multiple Myeloma with Extramedullary Disease and Plasma Cell Leukemia

2019 ◽  
Author(s):  
Chunrui Li ◽  
Wenyue Cao ◽  
Qiuxiang Wang ◽  
Yi Xiao ◽  
Chaojiang Gu ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Cell Therapy ◽  
Plasma Cell ◽  
Plasma Cell Leukemia ◽  
Cell Leukemia ◽  
T Cell Therapy ◽  
Refractory Multiple Myeloma ◽  
Car T Cell Therapy ◽  
Car T

scholarly journals A phase I study of anti‐BCMA CAR T cell therapy in relapsed/refractory multiple myeloma and plasma cell leukemia

2021 ◽  
Vol 11 (3) ◽  
Author(s):  
Chunrui Li ◽  
Wenyue Cao ◽  
Yimei Que ◽  
Qiuxiang Wang ◽  
Yi Xiao ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Cell Therapy ◽  
Phase I ◽  
Plasma Cell ◽  
Phase I Study ◽  
Cell Leukemia ◽  
T Cell Therapy ◽  
Car T Cell Therapy ◽  
Car T

A phase 1 multicenter study evaluating KITE-585, an autologous anti-BCMA CAR T-cell therapy, in patients with relapsed/refractory multiple myeloma.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. TPS3103-TPS3103 ◽  
Author(s):  
Robert F. Cornell ◽  
Frederick Lundry Locke ◽  
Michael Russell Bishop ◽  
Robert Z. Orlowski ◽  
Sarah Marie Larson ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Cell Therapy ◽  
Multicenter Study ◽  
Phase 1 ◽  
T Cell Therapy ◽  
Refractory Multiple Myeloma ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T

Idecabtagene vicleucel (ide-cel) CAR T-cell therapy for relapsed and refractory multiple myeloma

2021 ◽  
Author(s):  
Larry D Anderson
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Cell Therapy ◽  
T Cell Therapy ◽  
Refractory Multiple Myeloma ◽  
Car T Cell ◽  
Car T Cell Therapy ◽  
Car T ◽  
The Us ◽  
Us Fda

Idecabtagene vicleucel (ide-cel), a novel chimeric antigen receptor (CAR) T-cell therapy targeting B-cell maturation antigen (BCMA), has recently gained approval by the US FDA for relapsed and refractory multiple myeloma (RRMM) after multicenter trials have demonstrated unprecedented results in this difficult-to-treat subgroup of patients. As the first CAR T-cell product approved for myeloma, ide-cel is poised to become a practice-changing treatment option. This first-in-class therapeutic offers hope for more durable remissions, as well as better quality of life, following a single infusion in a group of patients that previously had little hope. This paper reviews the ide-cel product in terms of design, pharmacology, efficacy and toxicity as described in studies reported to date.

bb2121 anti-BCMA CAR T-cell therapy in patients with relapsed/refractory multiple myeloma: Updated results from a multicenter phase I study.

2018 ◽  
Vol 36 (15_suppl) ◽  
pp. 8007-8007 ◽  
Author(s):  
Noopur S. Raje ◽  
Jesus G. Berdeja ◽  
Yi Lin ◽  
Nikhil C. Munshi ◽  
David Samuel DiCapua Siegel ◽  
...  
Keyword(s):  
Multiple Myeloma ◽  
T Cell ◽  
Cell Therapy ◽  
Phase I ◽  
Phase I Study ◽  
T Cell Therapy ◽  
Refractory Multiple Myeloma ◽  
Multicenter Phase ◽  
Car T Cell Therapy ◽  
Car T
Sign in / Sign up

Export Citation Format

Share Document